Evidence map›Paper›PMID 42230731›Full record

ArticleScientific reports2026

Inhibition of runt related transcription factor 1 with Ro24-7429 improves lung function in experimental models of idiopathic pulmonary fibrosis.

Thomas I Hirsch, William P Miller, Savas T Tsikis, Said Jose Arevalo-Alquichire, Bryan A Kaplan, Karim W Barake, Audrey L Gunawan, Timothy E Vanderleest, Aruvi Vijikumar, Jeysson Sanchez-Suarez and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Thomas I Hirsch *Vascular Biology Program of Boston Children's Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave, MA, 02115, Boston, USA.
William P Miller *Department of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Savas T TsikisVascular Biology Program of Boston Children's Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave, MA, 02115, Boston, USA.
Said Jose Arevalo-AlquichireDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Bryan A KaplanDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Karim W BarakeDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Audrey L GunawanDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Timothy E VanderleestDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Aruvi VijikumarDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Jeysson Sanchez-SuarezDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Scott C FligorVascular Biology Program of Boston Children's Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave, MA, 02115, Boston, USA.
Sarah Z WangVascular Biology Program of Boston Children's Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave, MA, 02115, Boston, USA.
Amy Shei PanVascular Biology Program of Boston Children's Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave, MA, 02115, Boston, USA.
Mikayla QuigleyVascular Biology Program of Boston Children's Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave, MA, 02115, Boston, USA.
Mari KamiyaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Edy Y KimDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Michael O'HareDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Anton LennikovDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA.
Leo A KimDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, 20 Staniford st, MA, 02114, Boston, USA. Leo_Kim@meei.harvard.edu.
Mark PuderVascular Biology Program of Boston Children's Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave, MA, 02115, Boston, USA. Mark.Puder@childrens.harvard.edu.

Funding

HARVARD-LONGWOOD RESEARCH TRAINING IN VASCULAR SURGERYT32HL007734 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1993 to 2023
$10.5M
RESEARCH TRAINING IN ALIMENTARY TRACT SURGERYT32DK007754 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI HODIN, RICHARD A. · 1997 to 2025
$6.5M
NHLBI NIH HHS T32 HL007734NIDDK NIH HHS T32 DK007754NIH HHS 2T32DK007754-22NIH HHS 5T32HL007734
6 · The paper itself

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a life limiting disease with debilitating symptoms and limited therapeutic options. The development of IPF is a chronic process involving epithelial-to-mesenchymal transition (EMT), perpetuated by fibroblast proliferation and abnormal wound healing during which normal lung tissue is replaced with collagen impairing lung expansion and aeration. We targeted Runt-related transcription factor 1 (RUNX1), a transcription factor that coordinates EMT upon stimulation by key inflammatory mediators, such as TGF-β and TNF-α. In a previous investigation performed during the COVID19 pandemic, inhibiting RUNX1 with the small molecule inhibitor Ro24-7429 (Ro24), which has undergone testing in humans with a favorable side effect profile, was linked to a robust amelioration of lung fibrosis and decreased markers of fibrosis. In prior work utilizing Ro24, no studies of pulmonary function were performed and investigation of RUNX1 in human lung tissue was limited. Herein, we identified abnormally elevated RUNX1 in diseased human lung tissue of seven patients with IPF, implicating the transcription factor in the progression of the disease. Targeting RUNX1 with the small molecule inhibitor, Ro24 improved lung function and exercise tolerance in a murine model of bleomycin-induced pulmonary fibrosis. In comparison to the currently used clinical standards nintedanib and pirfenidone, Ro24 improved exercise tolerance in bleomycin-challenged mice. Thus, Ro24 has strong translational potential as a preventative therapy for patients with IPF.

Indexed as

Core Binding Factor Alpha 2 SubunitIdiopathic Pulmonary FibrosisLungAnimalsBleomycinDisease Models, AnimalEpithelial-Mesenchymal TransitionFemaleHumansIndolesMaleMiceMice, Inbred C57BLBleomycinCore Binding Factor Alpha 2 SubunitIndolesRUNX1 protein, humanBleomycin-induced pulmonary fibrosisFibrotic remodelingIdiopathic pulmonary fibrosisPrecision-cut lung slicesRo24-7429RUNX1

Identifiers

PMID42230731
PMCPMC13463064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.